Business
Dyadic Announces New Milestone as G2 Human Like Glycosylation Reached
Further Extends Company's Biologic Market OpportunitiesJUPITER, FL / ACCESSWIRE / February 24, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a
About this update from Dyadic International, Inc.
[{"type":"text","content":"Further Extends Company's Biologic Market OpportunitiesJUPITER, FL / ACCESSWIRE / February 24, 2020 / Dyadic International, Inc. (\"Dyadic\") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, announced that data presented at the 15th European Conference on Fungal Genetics (\"ECFG15\") demonstrated that its C1 strain has been glyco-engineered to achieve a core human like G2 glycan level over 76% on Host Cell Proteins (HCP).The G2 glycosylation data was presented by Anne Huuskonen from the VTT Technical Research Centre of Finland Ltd (\"VTT\") at the ECFG15 conference in Rome, Italy on Wednesday, February 19. The scientific results are outlined in the presentation entitled, ''Development of filamentous fungus Myceliophthora thermophila C1 into a next-generation therapeutic protein production system.\" An overview of the presentation is available on Dyadic's website at:https://www.dyadic.com/wp-content/uploads/2020/02/VTT-AHuuskonen-Rome-2-19-2020.pdf\"Our collaboration with Dyadic continues to achieve new scientific milestones regarding glycoengineering Dyadic's C1 industrially proven cell line, building upon the 95% core human G0 glycosylation milestone that was reported by Markku Saloheimo, Ph.D., Senior Principal Scientist at VTT, during the PEGS Europe (Protein & Antibody Engineering Summit) in November 2019,\" said Anne Huuskonen, VTT Senior Scientist.\"Our C1 glycoengineering efforts continue to target our goals in developing C1 cell lines that produce high proportions of human-like glycoforms such as G0, G2, G0F and G2F on heterologous proteins,\" said Ronen Tchelet, Ph.D., Dyadic's Chief Scientific Officer. \"In addition to the glycosylation results, VTT also presented data showing that we continue to make excellent progress in reducing the extracellular protease background by fifty (50) times in C1. The elimination of protease activity makes the C1 cell line more efficient, leading to even higher expression levels and lower cost than before.\"\"We are very pleased to announce this additional milestone,\" Matthew Jones, Dyadic's Chief Commercial Officer stated, \"These important ...